Trials / Completed
CompletedNCT00659750
To Assess the Safety and Efficacy of Ciclesonide Applied as a Nasal Spray in the Treatment of Perennial Allergic Rhinitis (BY9010/M1-402)
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Clinical Trial to Assess the Safety and Efficacy of Ciclesonide, Applied as a Nasal Spray (200 mg Once Daily) in the Treatment of Perennial Allergic Rhinitis (PAR) in Patients 12 Years and Older
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 418 (actual)
- Sponsor
- AstraZeneca · Industry
- Sex
- All
- Age
- 12 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study is to demonstrate the efficacy of ciclesonide applied as a nasal spray once daily in patients with PAR. The secondary objectives are to evaluate Quality-of-Life and safety.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ciclesonide | 200µg Ciclesonide versus Placebo |
| DRUG | Placebo | placebo |
Timeline
- Start date
- 2003-12-01
- Primary completion
- 2004-05-01
- Completion
- 2005-04-01
- First posted
- 2008-04-16
- Last updated
- 2016-12-02
Locations
23 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00659750. Inclusion in this directory is not an endorsement.